Effect of gefitinib on brain metastases from non-small cell lung cancer - Two case reports

Neurologia Medico-Chirurgica

Volumn 46, Issue 10, 2006, Pages 504-507

  Nishi, Noriyuki ^a   Kawai, Shozo ^a   Yonezawa, Taiji ^a   Fujimoto, Kenta ^a   Masui, Katsuya ^a  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

Author keywords

Brain metastasis; Epidermal growth factor receptor; Gefitinib; Molecular target therapy; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GADOLINIUM; GEFITINIB; GEMCITABINE;

ADENOCARCINOMA; ADULT; AGED; ANAMNESIS; ARTICLE; BRAIN METASTASIS; BRAIN TUMOR; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFECT; FEMALE; GAMMA KNIFE RADIOSURGERY; HISTOPATHOLOGY; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; LABORATORY TEST; LEFT HEMISPHERE; LUNG INJURY; LUNG NON SMALL CELL CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL EDEMA; RADIATION DOSE; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; QUINAZOLINES; TREATMENT OUTCOME;

EID: 33750505912     PISSN: 04708105     EISSN: 13498029     Source Type: Journal    
DOI: 10.2176/nmc.46.504     Document Type: Article

References (24)

1. Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, Woodburn JR, Ashton SE, Curry BJ, Scarlett L, Henthorn L, Richards L: Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 11: 1911-1914, 2001
2. Cappuzzo F, Ardizzoni A, Soto-Parra H, Gridelli C, Maione P, Tiseo M, Calandri C, Bartolini S, Santoro A, Crino L: Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer 41: 227-231, 2003
3. Cappuzzo F, Calandri C, Bartolini S, Crino L: ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases. Br J Cancer 89: 246-247, 2003
4. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7: 1459-1465, 2001
5. Cohen EEW, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21: 1980-1987, 2003
6. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R: FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8: 303-306, 2003
7. Committee of Brain Tumor Registry of Japan: Report of Brain Tumor Registry of Japan (1969-1996). Neurol Med Chir (Tokyo) 43 Suppl: i-vii, 1-111, 2003
8. Drucker B, Bacik J, Ginsberg M, Marion S, Russo P, Mazumdar M, Motzer R: Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs 21: 341-345, 2003
9. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi H, Angeletti CA, Pingitore R, Pepe S, Basolo F, Bevilacqua G: Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer 31A: 178-183, 1995
10. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21: 2237-2246, 2003
11. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 22: 777-784, 2004
12. Gullick WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 47: 87-98, 1991
13. Heimberger AB, Learn CA, Archer GE, McLendon RE, Chewning TA, Tuck FL, Pracyk JB, Friedman AH, Friedman HS, Bigner DD, Sampson JH: Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res 8: 3496-3502, 2002
14. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 22: 785-794, 2004
15. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T: Severe acute interstitial pneumonia and gefitinib. Lancet 361: 137-139, 2003
16. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149-2158, 2003
17. Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT, Abrey LE: High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 103: 2344-2348, 2005
18. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE 2nd, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS: Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22: 133-142, 2004
19. Roggero E, Busi G, Palumbo A, Pedrazzini A: Gefitinib ('Iressa', ZD1839) is active against brain metastases in a 77 year old patient. J Neurooncol 71: 277-280, 2005
20. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232, 1995
21. Vesagas TS, Aguilar JA, Mercado ER, Mariano MM: Gamma knife radiosurgery and brain metastases: local control, survival, and quality of life. J Neurosurg 97(5 Suppl): 507-510, 2002
22. Villano JL, Mauer AM, Vokes EE: A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain. Ann Oncol 14: 656-658, 2003
23. Wakeling AE, Barker AJ, Davies DH, Brown DS, Green LR, Cartlidge SA, Woodburn JR: Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat 38: 67-73, 1996
24. Yano S, Yamaguchi M, Dong RP: EGFR tyrosine kinase inhibitor "gefitinib (Iressa)" for cancer therapy. Nippon Yakurigaku Zasshi 122: 491-497, 2003